报价延迟最少15分钟:2025/08/25 04:52 EDT
盘前时段
|
||||
|
6.22 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.38
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-12,356.89/3.14
|
|
企业价值
4.19M
|
| 资产负债 |
|
每股账面净值
8.61
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
520.00K
|
|
每股收益
1.21
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/25 04:52 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. |
